\babel@toc {english}{}
\contentsline {chapter}{\numberline {1}Transcription}{6}{chapter.1}%
\contentsline {section}{\numberline {1.1}Transcription initiation}{6}{section.1.1}%
\contentsline {section}{\numberline {1.2}Chromatin remodeling}{8}{section.1.2}%
\contentsline {subsubsection}{\numberline {1.2.0.1}Techniques to study chromatin remodelling}{8}{subsubsection.1.2.0.1}%
\contentsline {section}{\numberline {1.3}Nucleosome organization}{9}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Nucleosome remodelling}{9}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Chromatin Immunoprecipitation}{11}{subsection.1.3.2}%
\contentsline {subsection}{\numberline {1.3.3}Main nucleosome modifications in promoters}{11}{subsection.1.3.3}%
\contentsline {subsection}{\numberline {1.3.4}RT-qPCR based detection of 5' RNA transcripts of inactive genes}{12}{subsection.1.3.4}%
\contentsline {subsection}{\numberline {1.3.5}Global run-on sequencing (GRO-seq)}{13}{subsection.1.3.5}%
\contentsline {subsection}{\numberline {1.3.6}Transcription pausing mechanism}{14}{subsection.1.3.6}%
\contentsline {section}{\numberline {1.4}Transcription elongation}{15}{section.1.4}%
\contentsline {subsection}{\numberline {1.4.1}Structural basis of the nucleosome transition during RNA pol II passage}{15}{subsection.1.4.1}%
\contentsline {subsubsection}{\numberline {1.4.1.1}Nucleosome structure}{15}{subsubsection.1.4.1.1}%
\contentsline {subsubsection}{\numberline {1.4.1.2}Cryo-EM}{15}{subsubsection.1.4.1.2}%
\contentsline {subsubsection}{\numberline {1.4.1.3}Summary of the main results}{17}{subsubsection.1.4.1.3}%
\contentsline {subsection}{\numberline {1.4.2}Template looping}{17}{subsection.1.4.2}%
\contentsline {subsection}{\numberline {1.4.3}Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT}{18}{subsection.1.4.3}%
\contentsline {section}{\numberline {1.5}Transcription termination}{18}{section.1.5}%
\contentsline {subsection}{\numberline {1.5.1}Promoter reporter assay}{19}{subsection.1.5.1}%
\contentsline {subsection}{\numberline {1.5.2}Promoter types}{20}{subsection.1.5.2}%
\contentsline {subsection}{\numberline {1.5.3}Transcription factor binding}{20}{subsection.1.5.3}%
\contentsline {chapter}{\numberline {2}Transcription regulation and its deregulation in cancer}{22}{chapter.2}%
\contentsline {section}{\numberline {2.1}Mediator complex}{22}{section.2.1}%
\contentsline {section}{\numberline {2.2}Wnt signalling pathway}{24}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}$\beta $-catenin structure}{25}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}The canonical Wnt $\beta $-catenin pathway is crucially involved in colorectal cancer}{26}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}CBP/p300}{27}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}CBP/p300 structure}{27}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}CBP/p300 in cancer}{29}{subsection.2.3.2}%
\contentsline {section}{\numberline {2.4}TSSa-RNAs transcription}{29}{section.2.4}%
\contentsline {section}{\numberline {2.5}Enhancers}{30}{section.2.5}%
\contentsline {subsection}{\numberline {2.5.1}Properties of eRNAs}{31}{subsection.2.5.1}%
\contentsline {subsection}{\numberline {2.5.2}eRNAs proposed functions}{31}{subsection.2.5.2}%
\contentsline {section}{\numberline {2.6}Assessing whether the CRC 8q24 risk region acts as an enhancer}{31}{section.2.6}%
\contentsline {section}{\numberline {2.7}The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling}{33}{section.2.7}%
\contentsline {section}{\numberline {2.8}CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instabilty in colon cancer}{34}{section.2.8}%
\contentsline {chapter}{\numberline {3}Chromosome domains and oncogene activation}{37}{chapter.3}%
\contentsline {section}{\numberline {3.1}Genome organization and transcription regulation}{37}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}CTCF}{37}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Cohesin mediates transcriptional insulation by CCCTC-binding factor}{38}{subsection.3.1.2}%
\contentsline {subsection}{\numberline {3.1.3}CTCF and Cohesin in Genome Folding and Transcriptional Gene Regulation}{40}{subsection.3.1.3}%
\contentsline {section}{\numberline {3.2}Chromosome Conformation Capture (3C)}{41}{section.3.2}%
\contentsline {section}{\numberline {3.3}Hi-C approach}{41}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Optimization of Hi-C approach}{43}{subsection.3.3.1}%
\contentsline {section}{\numberline {3.4}Mediator and cohesin connect gene expression and chromatin architecture}{45}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods}{46}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Depletion of Mediator causes loss of PIC assembly}{47}{subsection.3.4.2}%
\contentsline {section}{\numberline {3.5}Super-enhancers}{48}{section.3.5}%
\contentsline {subsection}{\numberline {3.5.1}How is a SE generated during tumorigenesis?}{49}{subsection.3.5.1}%
\contentsline {subsection}{\numberline {3.5.2}How cancer cells take advantage of super-enhancers}{49}{subsection.3.5.2}%
\contentsline {section}{\numberline {3.6}The role of MYC in cancer cells}{50}{section.3.6}%
\contentsline {subsection}{\numberline {3.6.1}Key aspects of MYC in tumorigenesis}{51}{subsection.3.6.1}%
\contentsline {subsubsection}{\numberline {3.6.1.1}MYC transcription factor forms a heterodimer with MAX}{51}{subsubsection.3.6.1.1}%
\contentsline {subsection}{\numberline {3.6.2}By which major mechanism or pathway do MYC proteins promote tumorigenesis?}{52}{subsection.3.6.2}%
\contentsline {chapter}{\numberline {4}Targeting transcription in cancer}{55}{chapter.4}%
\contentsline {section}{\numberline {4.1}Age-related remodellling of oesophageal epithelia by mutated cancer drivers}{55}{section.4.1}%
\contentsline {section}{\numberline {4.2}The risk of suffering any cancer increases during aging}{57}{section.4.2}%
\contentsline {section}{\numberline {4.3}Targeted therapeutics generally lead to resistance}{58}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}Mutations in cancer}{58}{subsection.4.3.1}%
\contentsline {section}{\numberline {4.4}Target transcription in cancer}{59}{section.4.4}%
\contentsline {section}{\numberline {4.5}BRD4}{61}{section.4.5}%
\contentsline {subsection}{\numberline {4.5.1}Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers}{61}{subsection.4.5.1}%
\contentsline {section}{\numberline {4.6}YAP/TAZ}{62}{section.4.6}%
\contentsline {section}{\numberline {4.7}TEAD}{63}{section.4.7}%
\contentsline {subsection}{\numberline {4.7.1}YAP/TAZ/TEAD}{63}{subsection.4.7.1}%
\contentsline {section}{\numberline {4.8}Nuclear receptors}{64}{section.4.8}%
\contentsline {subsection}{\numberline {4.8.1}Estrogen receptor \(\alpha \)}{65}{subsection.4.8.1}%
\contentsline {subsection}{\numberline {4.8.2}ER$\alpha $ in breast cancer}{65}{subsection.4.8.2}%
\contentsline {subsubsection}{\numberline {4.8.2.1}Mechanisms provoking breast cancer drug resistance}{67}{subsubsection.4.8.2.1}%
\contentsline {subsubsection}{\numberline {4.8.2.2}Summary}{67}{subsubsection.4.8.2.2}%
\contentsline {subsubsection}{\numberline {4.8.2.3}ER$\alpha $ transcriptional program}{68}{subsubsection.4.8.2.3}%
\contentsline {chapter}{\numberline {5}Genome instability and DNA damage response and repair}{70}{chapter.5}%
\contentsline {section}{\numberline {5.1}R-loops}{70}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}R-loop degradation}{71}{subsection.5.1.1}%
\contentsline {subsection}{\numberline {5.1.2}R-loop recognition and distribution}{71}{subsection.5.1.2}%
\contentsline {subsection}{\numberline {5.1.3}VIM-antisense1}{72}{subsection.5.1.3}%
\contentsline {subsection}{\numberline {5.1.4}HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{73}{subsection.5.1.4}%
\contentsline {subsection}{\numberline {5.1.5}HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{75}{subsection.5.1.5}%
\contentsline {section}{\numberline {5.2}DNA damage}{75}{section.5.2}%
\contentsline {section}{\numberline {5.3}R loop modified bases}{76}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Apical kinases}{76}{subsection.5.3.1}%
\contentsline {subsection}{\numberline {5.3.2}Topoisomerases}{79}{subsection.5.3.2}%
\contentsline {subsubsection}{\numberline {5.3.2.1}A topoisomerase IIb-mediated dsDNA break required for Regulated Transcription}{79}{subsubsection.5.3.2.1}%
\contentsline {subsubsection}{\numberline {5.3.2.2}BRCA1}{80}{subsubsection.5.3.2.2}%
\contentsline {subsubsection}{\numberline {5.3.2.3}Stark et al.}{80}{subsubsection.5.3.2.3}%
\contentsline {section}{\numberline {5.4}DNA damage signaling activation during tumorigenesis}{81}{section.5.4}%
\contentsline {subsection}{\numberline {5.4.1}Which tumorigenic events trigger activation DDR?}{81}{subsection.5.4.1}%
\contentsline {subsection}{\numberline {5.4.2}Oncogene induced senescence cells}{83}{subsection.5.4.2}%
\contentsline {subsubsection}{\numberline {5.4.2.1}Replication stress}{84}{subsubsection.5.4.2.1}%
\contentsline {subsubsection}{\numberline {5.4.2.2}Chromosome abnormalities due to pre-mitotic defects are frequently found in tumors}{87}{subsubsection.5.4.2.2}%
\contentsline {subsubsection}{\numberline {5.4.2.3}Transcription replication conflicts}{88}{subsubsection.5.4.2.3}%
\contentsline {subsubsection}{\numberline {5.4.2.4}Increased global transcription activity as a mechanism of replication stress in cancer}{91}{subsubsection.5.4.2.4}%
\contentsline {section}{\numberline {5.5}Biogenesis of canonical miRNA}{93}{section.5.5}%
\contentsline {section}{\numberline {5.6}DICER and DROSHA regulation of DDR and checkpoint enforcement}{93}{section.5.6}%
\contentsline {section}{\numberline {5.7}DDRNAs}{94}{section.5.7}%
\contentsline {subsection}{\numberline {5.7.1}DDRNAs and dilncRNAs regulate DDR and DNA repair}{96}{subsection.5.7.1}%
\contentsline {section}{\numberline {5.8}RNA Pol II recruitment at DSBs}{97}{section.5.8}%
\contentsline {chapter}{\numberline {6}Telomeres and telomere transcription in cancer}{98}{chapter.6}%
\contentsline {section}{\numberline {6.1}What are telomeres?}{98}{section.6.1}%
\contentsline {section}{\numberline {6.2}Telomeres mask chromosome ends from being recognized as double-strand breaks}{98}{section.6.2}%
\contentsline {section}{\numberline {6.3}Telomere dysfunction in a p53 and Rb mutant setting does not induce cell cycle block}{99}{section.6.3}%
\contentsline {section}{\numberline {6.4}End of replication problem}{100}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Hayflick limit}{101}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}Triggering senescence}{102}{subsection.6.4.2}%
\contentsline {section}{\numberline {6.5}Cell crisis}{102}{section.6.5}%
\contentsline {section}{\numberline {6.6}Telomerase enzyme}{103}{section.6.6}%
\contentsline {subsection}{\numberline {6.6.1}Usage of telomerase}{104}{subsection.6.6.1}%
\contentsline {chapter}{\numberline {7}Journal Clubs}{105}{chapter.7}%
\contentsline {section}{\numberline {7.1}Mechansims of transcription regulation}{105}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release}{105}{subsection.7.1.1}%
\contentsline {subsection}{\numberline {7.1.2}SPT5 stabilization of promoter - proximal RNA polymerase II}{106}{subsection.7.1.2}%
\contentsline {section}{\numberline {7.2}Mechanisms of transcription regulation in cancer}{108}{section.7.2}%
\contentsline {subsection}{\numberline {7.2.1}MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation}{108}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer}{110}{subsection.7.2.2}%
\contentsline {subsection}{\numberline {7.2.3}HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state}{112}{subsection.7.2.3}%
\contentsline {subsection}{\numberline {7.2.4}Oncogenic lncRNAs alter epigenetic memory at a fragile chromosomal site in human cancer cells}{113}{subsection.7.2.4}%
\contentsline {section}{\numberline {7.3}Targeting transcription in cancer}{114}{section.7.3}%
\contentsline {subsection}{\numberline {7.3.1}Targeting histone acetylation dynamics and oncogenic transcription by catalytic p300/CBP inhibition}{114}{subsection.7.3.1}%
\contentsline {subsection}{\numberline {7.3.2}Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma}{116}{subsection.7.3.2}%
\contentsline {subsection}{\numberline {7.3.3}Transcription elongation factors represent in vivo cancer dependencies in glioblastoma}{117}{subsection.7.3.3}%
\contentsline {section}{\numberline {7.4}Nuclear receptors in cancer}{118}{section.7.4}%
\contentsline {subsection}{\numberline {7.4.1}ER$\alpha $ is an RNA-binding protein sustaining tumor cell survival and drug resistance}{118}{subsection.7.4.1}%
\contentsline {subsection}{\numberline {7.4.2}Analysis of estrogen-regulated enhancer RNAs identified a functional motif required for enhancer assembly and gene expression}{120}{subsection.7.4.2}%
